| Name | Title | Contact Details |
|---|
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
SantenUSA.com - a specialty pharmaceutical offering ophthalmic products & research for retinal disorders, glaucoma, and other eye diseases.
Cambridge Major Laboratories is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries
R2P creates a unique physical therapy experience, offering our blend of performance, return to sport, physical therapy, dry needling and injury prevention.